Skip to main content

Market Overview

Cashing COVID-19 Vaccine - AstraZeneca Or Pfizer

Share:
Cashing COVID-19 Vaccine - AstraZeneca Or Pfizer

Today AstraZeneca plc (NASDAQ: AZN) released its second-quarter earnings with updated sales numbers for its COVID-19 vaccine; when compared to the big mRNA players, the numbers looked rather pale.

Q2 Sales Numbers: AstraZeneca's COVID-19 jab clocked in about $1.17 billion globally in the first half, including $894 million in the second quarter alone

Pfizer Inc's (NYSE: PFE) vaccine sales have soared with $3.5 billion in Q1 and another $7.8 billion in the second quarterModerna Inc (NASDAQ: MRNA), which is slated to report its second-quarter results next week, bagged $1.7 billion in COVID-19 vaccine sales in Q1.

Pfizer's sales jump has encouraged it to raise full-year projections to $33.5 billion, up from $26 billion in May and $15 billion in February. 

Let's Compare the Prices: Last week, when the U.S. called for additional 200 million doses of the Pfizer vaccine, it paid about $24/dose, up from the $19.50 in its earlier deals to supply. However, AstraZeneca is selling its vaccines at cost to low- and middle-income countries, which is a potential basis for the Company to decline to disclose full-year projections for its shot. 

In one example, AZN sold its shots to South Africa at $5.25 per dose, while Pfizer charged about $10 per dose. Albert Bourla wrote in a letter to employees, some lower-income countries didn't even bother ordering or authorizing the Pfizer vaccine at all, with the majority reserved by high-income nations.

Additionally, AstraZeneca's vaccine is still not authorized in the U.S. following safety issues and a dispute over efficacy data. But CEO Pascal Soriot appears to have gotten the ball rolling outside the U.S. in recent months. 

Recent real-world data from Canada showed similar levels in reducing severe illness, hospitalizations, and deaths to the mRNA shots. Also, a person's risk of blood clots does not increase after the second AZN COVID-19 vaccine shot.

AstraZeneca confirmed in its earnings call that it would be seeking a full FDA approval for its vaccine in the U.S. rather than shoot for an emergency use authorization. 

Soriot also took a contrasting position with Bourla on booster shots, telling a CNBC Europe, the Company did not have a "precise answer" on whether a booster would be required.

Price Action: AZN shares are up 1.50% at press time, while PFE shares are down 1.55% on Thursday.

Photo by Johaehn from Pixabay

 

Related Articles (PFE + BNTX)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Guidance Health Care Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com